The Trump administration is running out of time to select a nominee to run the CDC if it wants NIH Director Jay Bhattacharya, who’s also serving as the CDC’s acting director, to stay in dual roles.

A 2023 law championed by Republicans requires the CDC have a director confirmed by the Senate. For months, though, it’s had only acting directors—and the White House won’t say when that will change.

As the Trump administration shakes up recommendations for childhood vaccines, some states are moving to ensure vaccines remain free and health care workers are protected from lawsuits.

The principal deputy director of the Centers for Disease Control and Prevention, Dr. Ralph Abraham, abruptly stepped down from his position Monday, the agency announced, citing “unforeseen family ...

A Kansas House committee added a budget proviso to mandate the state follow new federal childhood vaccine guidance. The CDC recently reduced the number of universally recommended childhood vaccines ...

NEW YORK (Reuters) – Two Democratic state attorneys general announced a multistate lawsuit against the Trump administration on Tuesday over recent changes to the federal government’s childhood vaccine ...

In a race to attract billions of dollars in investment from artificial intelligence giants, data centre industry insiders say Victoria is outperforming NSW.

Washington lawmakers have approved a proposal from Gov. Bob Ferguson and Insurance Commissioner Patty Kuderer to shift authority over vaccine and other preventi ...

National Institutes of Health director Jay Bhattacharya will also become acting director of the Centers for Disease Control and Prevention as the Trump administration continues a shakeup of its senior ...

WASHINGTON (AP) — National Institutes of Health Director Jay Bhattacharya will also temporarily become acting director of the Centers for Disease Control and Prevention, an administration official ...

Start your morning with The National News Desk as Jan Jeffcoat sits down with President and CEO of Airlines for America Chris Sununu to discuss [SUBJECT MATTER] ...

As Congress mulls whether to follow President Donald Trump’s orders for a most-favored-nation drug-pricing policy, biotech firm executives are starting to speak out against the measure.